• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CYCN

CYCN

Cyclerion Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.00

-0.02 (-0.66%)

Rating:C

Company Profile

CEO

Regina Graul

IPO Date

2019-03-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.00

Prev. Close

$3.02

Day Low

$2.98

Day High

$3.04

52W Low

$1.03

52W High

$8.48

Market Cap

$0.01B

Volume

0.03M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

56.1%

Avg Negative

1.1%

Avg Neutral

42.9%

News Feed

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

GlobeNewsWire·8/23/2021·↑ positive

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

GlobeNewsWire·7/29/2021·↑ positive

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

GlobeNewsWire·7/22/2021·↑ positive

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Benzinga·7/9/2021·↑ positive

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

PRNewsWire·7/8/2021·↑ positive

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

GlobeNewsWire·7/8/2021·↑ positive

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

GlobeNewsWire·6/4/2021·↑ positive

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

GlobeNewsWire·5/27/2021·↑ positive

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

CYCN Stock: Over 5% Increase Pre-Market Explanation

Pulse2·5/7/2021·↑ positive